## Mario Fioravanti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4170748/publications.pdf

Version: 2024-02-01

623188 476904 1,585 32 14 29 citations g-index h-index papers 32 32 32 2497 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Is urinary 1-hydroxypyrene a valid biomarker for exposure to air pollution in outdoor workers? A meta-analysis. Journal of Exposure Science and Environmental Epidemiology, 2014, 24, 17-26.	1.8	46
2	A systematic review and meta-analysis assessing adverse event profile and tolerability of nicergoline. BMJ Open, 2014, 4, e005090-e005090.	0.8	23
3	Cadmium and hypertension in exposed workers: A meta-analysis. International Journal of Occupational Medicine and Environmental Health, 2013, 26, 440-56.	0.6	43
4	Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia. Alzheimer's and Dementia, 2013, 9, e96-e105.	0.4	66
5	Authors' response to 'Comments on Sancini et al.'. Occupational Medicine, 2013, 63, 162-162.	0.8	O
6	Differences between the aging process and the chronic cerebrovascular impairment of memory functioning: the emotional and cognitive interaction. Reviews in the Neurosciences, 2012, 23, 691-6.	1.4	0
7	Differential characteristics of the aging process and the vascular cognitive impairment in the organization of memory retrieval. Journal of the Neurological Sciences, 2012, 322, 148-151.	0.3	5
8	Cognitive deficits in schizophrenia: an updated metanalysis of the scientific evidence. BMC Psychiatry, 2012, 12, 64.	1.1	309
9	Therapeutic Use of Nicergoline. Clinical Drug Investigation, 2008, 28, 533-552.	1.1	67
10	Relationship between memory, attention, and depression in chronic cerebro-vascular patients. Journal of the Neurological Sciences, 2007, 257, 155-159.	0.3	1
11	Citicoline (Cognizin) in the treatment of cognitive impairment. Clinical Interventions in Aging, 2006, 1, 247-251.	1.3	41
12	A Meta-Analysis of Cognitive Deficits in Adults with a Diagnosis of Schizophrenia. Neuropsychology Review, 2005, 15, 73-95.	2.5	382
13	Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. The Cochrane Library, 2005, , CD000269.	1.5	120
14	History of Symptomatic Therapy in Vascular Dementia. International Psychogeriatrics, 2003, 15, 177-181.	0.6	2
15	Nicergoline for dementia and other age associated forms of cognitive impairment. The Cochrane Library, 2001, , CD003159.	1.5	51
16	Memory rehabilitation in Alzheimer's disease: a review of progress. International Journal of Geriatric Psychiatry, 2001, 16, 794-809.	1.3	206
17	Memory rehabilitation in Alzheimer's disease: a review of progress. , 2001, 16, 794.		2
18	The relevance of continuous blood pressure monitoring in examining the relationship of memory efficiency with blood pressure characteristics. Physiology and Behavior, 1996, 59, 1077-1084.	1.0	7

#	Article	IF	CITATIONS
19	Quality of life in chronic diseases of the aged: the importance of cognitive deterioration. Archives of Gerontology and Geriatrics, 1996, 22, 195-205.	1.4	4
20	Chronic Obstructive Pulmonary Disease and Associated Patterns of Memory Decline. Dementia and Geriatric Cognitive Disorders, 1995, 6, 39-48.	0.7	14
21	The Italian version of the Alzheimer's Disease Assessment Scale (ADAS): psychometric and normative characteristics from a normal aged population. Archives of Gerontology and Geriatrics, 1994, 19, 21-30.	1.4	31
22	Memory Improvements and Pharmacological Treatment: A Method to Distinguish Direct Effects on Memory from Secondary Effects Due to Attention Improvement. International Psychogeriatrics, 1992, 4, 119-126.	0.6	7
23	CBF and cognitive evaluation of Alzheimer type patients before and after IMAO-B treatment: a pilot study. European Neuropsychopharmacology, 1992, 2, 31-35.	0.3	29
24	Forgetting curves in long-term memory: Evidence for a multistage model of retention. Brain and Cognition, 1992, 18, 116-124.	0.8	14
25	Randomized, double-blind, placebo controlled, multicentre study of idebenone in patients suffering from multi-infarct dementia. Archives of Gerontology and Geriatrics, 1992, 15, 239-248.	1.4	10
26	Idebenone in senile dementia of Alzheimer type: A multicentre study. Archives of Gerontology and Geriatrics, 1992, 15, 249-260.	1.4	65
27	Long-term idebenone treatment of vascular and degenerative brain disorders of the elderly. Archives of Gerontology and Geriatrics, 1992, 15, 261-269.	1.4	14
28	Measuring cognitive processes in patients with parkinson's disease. Archives of Clinical Neuropsychology, 1991, 6, 319-325.	0.3	1
29	Measuring cognitive processes in patients with parkinson's disease. Archives of Clinical Neuropsychology, 1991, 6, 319-325.	0.3	3
30	Monoamine Oxidase and Dementia: Treatment with an Inhibitor of MAO-B Activity. Dementia and Geriatric Cognitive Disorders, 1990, 1, 109-114.	0.7	4
31	A multidimensional approach to the assessment of clinical validity in a study on CCVD treatment: dihydroergocristine versus placebo. Archives of Gerontology and Geriatrics, 1987, 6, 83-93.	1.4	3
32	Some implications of self versus ideal-self congruence on the revised Adjective Check List Journal of Personality and Social Psychology, 1983, 44, 1214-1220.	2.6	15